Drug

Daiichi Sankyo's DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer
ADC / XDCAstraZeneca

Daiichi Sankyo’s DATROWAY Approved in China for New Indication – TROP2 ADC Extends Survival in Unresectable or Metastatic Triple‑Negative Breast Cancer

Daiichi Sankyo Company, Limited (TYO: 4568) announced that DATROWAY (datopotamab deruxtecan), its TROP2-directed antibody drug conjugate (ADC) jointly developed and commercialized with AstraZeneca, has been approved in China for a…

Innovent Biologics' Xinbimin Meets Primary Endpoint in Phase III RESTORE‑3 Trial – Significant Proptosis Improvement in Chinese Patients with Inactive Thyroid Eye Disease

Innovent Biologics’ Xinbimin Meets Primary Endpoint in Phase III RESTORE‑3 Trial – Significant Proptosis Improvement in Chinese Patients with Inactive Thyroid Eye Disease

SynRx Therapeutics' SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

SynRx Therapeutics’ SYN818 Plus Olaparib Wins FDA Fast Track Designation – First China-Developed Polθ Inhibitor Combination to Earn the Status

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Essight Bio's ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic
CancerClinical trial approval / initiation

Essight Bio’s ES502 Wins FDA Phase I Approval – First TCR×CD3 Bispecific Targeting RAS G12V Mutations Enters Clinic

CancerGeneScience Pharmaceutical

Changchun GeneScience’s GenSci128 Wins FDA Orphan Drug Designation – TP53 Y220C Reactivator Targets Pancreatic Cancer

Sino Biopharm's TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers
Chia Tai Tianqing PharmaceuticalClinical trial approval / initiation

Sino Biopharm’s TQB3205 Wins NMPA Approval – First China-Developed Pan-KRAS Inhibitor Enters Clinic for Advanced Cancers

ADC / XDCCancer

Huadong Medicine’s HDM2017 Wins FDA Orphan Drug Designation – CDH17 ADC Targets Three Gastrointestinal Cancers

Show More